Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary - Primary - GI - CALGB-80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary - Primary - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Basch, Ethan , Becker, Claus , Rogak, Lauren J , Schrag, Deborah ... - - Clin Trials - 2020 Manuscript - Secondary-not-in-original - Primary - Health Outcome - A091105
Her2 gene expression and not Her2 amplification is predictive and prognostic in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance) Battaglin, Francesca , Ou, Fang-Shu , Qu, Xueping ... - ASCO - J. Clin. Oncol - 2020 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405
What Happened to the US Cancer Cooperative Groups? A Status Update Ten Years After the IOM Report Bertagnolli, Monica M. , Blanke, Charles D. , Curran, Walter J. Jr ... - - Cancer - 2020 Manuscript - No-Endpoint - Other - -
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , CALGB-89803
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803 Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011 Manuscript - Primary - Primary - GI - C150705 , C89803 , C9581
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , C89803
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Goel, Ajay , Nagasaka, Takeshi , Arnold, Christian N , Inoue, Toru ... - - Gastroenterology - 2007 Manuscript - Secondary - Primary - GI - CALGB-9865
Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017 Abstract - Secondary - Preliminary - GI - CALGB-80405
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405 Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Heinrich, Michael C. , Owzar, Kouros , Corless, Christopher L. ... - - J Clin Oncol - 2008 Manuscript - Secondary - Primary - PPP - CALGB-150105
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome Innocenti, Federico , Ou, Fang-Shu , Qu, Xueping , Zemla, Tyler J. ... - - J. Clin. Oncol - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - PPP - CALGB-80405
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ECC - Eur J Cancer - 2015 Abstract - Secondary - Primary - PPP - CALGB-80405
Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance) Innocenti, Federico , Sibley, Alexander B. , Patil, Sushant A. ... - - Clin Cancer Res - 2021 Manuscript - Secondary - Primary - PPP - CALGB-80405
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P ... - - J. Clin. Oncol. - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - A151425 , CALGB-80405
Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803 Ng, Kimmie , Ogino, Shuji , Meyerhardt, Jeffrey A. ... - - J Natl Cancer Inst - 2011 Manuscript - Secondary - Primary - GI - C89803
Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581 Niedzwiecki, Donna , Bertagnolli, Monica M. , Warren, Robert S. ... - - J Clin Oncol - 2011 Manuscript - Primary - Primary - GI - C9581
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) Niedzwiecki, Donna , Frankel, Wendy L. , Venook, Alan P. , Ye, Xing ... - - J. Clin. Oncol - 2016 Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150705 , C9581
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803 Niedzwiecki, Donna , Hasson, Rian M. , Lenz, Heinz‐Josef ... - - Oncologist - 2017 Manuscript - Secondary-not-in-original - Meta-Analysis - GI - C89803 , C9581
Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance) Nixon, Andrew B. , Pang, Herbert , Starr, Mark D. ... - - Clin. Cancer Res. - 2013 Manuscript - Secondary - Primary - GI - CALGB-80303
Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial Ogino, Shuji , Liao, Xiaoyun , Imamura, Yu , Yamauchi, Mai ... - - J. Natl. Cancer Inst - 2013 Manuscript - Secondary - Primary - GI - CALGB-89803
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 Ogino, Shuji , Meyerhardt, Jeffrey A. , Irahara, Natsumi ... - - Clin Cancer Res - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , CALGB-89803
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 Ogino, Shuji , Shima, Kaori , Meyerhardt, Jeffrey A. ... - - Clin Cancer Res - 2012 Manuscript - Secondary - Primary - GI - CALGB-150705 , C89803
MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial Pavelitz, Thomas , Renfro, Lindsay , Foster, Nathan R. ... - - PLoS ONE - 2014 Manuscript - Secondary - Primary - GI - CALGB-89803
Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology Peppercorn, Jeffrey , Shapira, Iuliana , Collyar, Deborah ... - - J. Clin. Oncol - 2010 Manuscript - No-Endpoint - Comprehensive - Ethics - No Study Assigned
Association of RAS mutations with race in metastatic colorectal cancer CALGB 80405 (Alliance) Sehdev, Amikar , Niedzwiecki, Donna , Venook, Alan P. ... - ASCO GI - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405
CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer Shiovitz, Stacey , Bertagnolli, Monica M. , Renfro, Lindsay A. ... - - Gastroenterology - 2014 Manuscript - Secondary - Primary - GI - CALGB-89803
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - - J. Clin. Oncol - 2013 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-89803 , N0147
Impact of primary (1º) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance) Venook, Alan P. , Niedzwiecki, Donna , Innocenti, Federico ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary - Primary - GI - CALGB-80405
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer Venook, Alan P. , Niedzwiecki, Donna , Lenz, Heinz-Josef ... - - JAMA - 2017 Manuscript - Primary - Primary - GI - CALGB-80405
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Venook, Alan P. , Niedzwiecki, Donna , Lenz, Heinz-Josef ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - GI - CALGB-80405
Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581 Venook, Alan P. , Niedzwiecki, Donna , Lopatin, Margarita , Ye, Xing ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary - Primary - GI - C9581 , C150705
Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803 Warren, Robert S. , Atreya, Chloe E. , Niedzwiecki, Donna ... - - Clin. Cancer Res. - 2013 Manuscript - Secondary - Primary - GI - CALGB-89803
